All News

RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
patient.safety.jpg

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
lung%2Cbright.jpg

Lung Cancer Survival With Autoimmune Disease

Jack Cush, MD

Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
Cancer.risk_.jpg

ICI Arthritis Tied to Cancer Progression

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.

Read Article
Lupus.right_.jpg

In Lupus, Older Age and Male Sex Raise Cancer Risk

RheumNow

Among patients with systemic lupus erythematosus (SLE), cancer risks overall were associated with older age at diagnosis and male sex, and lung cancer specifically was related to smoking, analysis of data from a large multicenter cohort found.

Read Article
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets "RT @drdavidliew : Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y

Links:

Dr. John Cush RheumNow ( View Tweet)
There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

Chris Wincup chriswincup ( View Tweet)

Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
David Liew drdavidliew ( View Tweet)
This cohort study presented by @Dr_Alex_Oldroyd shows that early cancer diagnosis after #myositis onset is associated with significantly improved survival. Cancer screening essential in pts newly diagnosed with IIMs. @RheumNow #ACR20 abs1057 https://t.co/qVsnTcEnWb
sheila RHEUMarampa ( View Tweet)
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
Richard Conway RichardPAConway ( View Tweet)
IL-6 blockade for management of irAEs without inhibiting anti cancer immune response. Should these be given prior or concomitantly with ICIs? Some interesting ideas to look up from the cancer and immunotherapy study group. #ACR20 @UTSWNews @ACRheum @RheumNow

Adela Castro AdelaCastro222 ( View Tweet)

Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow

Eric Dein ejdein1 ( View Tweet)

Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity

Links:

Peter Nash drpnash ( View Tweet)

Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

FDA Issues Final Guidance for Labeling Recommendations on Breast Implants, after review of data & commentary. Implants have been assoc w/anaplastic large cell lymphoma & breast implant illness (BII) w/ fatigue, “brain fog,” rash, myalgia, arthralgia. . https://t.co/HozSCRx4JH

Links:

Dr. John Cush RheumNow ( View Tweet)

Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD. TIF1γ was associ w/ refractory rash and cancer https://t.co/3E365F5SON

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×